BERLIN & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced positive topline results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital that evaluated the investigational PET/CT radiotracer I 124 evuzamitide.1,5 The study met the primary endpoints of sensitivity (the ability of a test to identify individuals who have the condition) and specificity (the ability of a test to identify individuals who do not have the condition) for the diagnosis of cardiac amyloidosis based on visual scan interpretation.1 Bayer plans to present the complete results at an upcoming scientific congress.
I 124 evuzamitide is an investigational PET radiotracer–a radioactive diagnostic imaging agent injected into the body before a PET scan to assist with visualization–being studied in patients with suspected cardiac amyloidosis.5 I 124 evuzamitide is an investigational compound and has not been approved by any health authority for use in any country for any indication.